Skip to main content
. 2018 Mar 25;72(7):1180–1188. doi: 10.1111/his.13491

Figure 3.

Figure 3

Five‐year overall survival stratified by combined tumour regression grade (TRG) in patients treated with neoadjuvant chemotherapy plus surgery in the OE02 trial. Patients with TRG1–3 tumours (responders) survived significantly longer than patients with TRG4–5 tumours (non‐responders) [hazard ratio (HR) = 1.53, 95% confidence interval (CI) = 1.05–2.24, P = 0.026].